Terminal β-galactose residues on cell-surface N-linked glycans (Terminal β-gal)

Terminal β-galactose residues are critical carbohydrate determinants located at the non-reducing ends of N-linked glycan chains on cell-surface and secreted glycoproteins. In healthy tissues, these residues are typically masked by terminal sialic acids, but their exposure—often termed desialylation—acts as a molecular signal recognized by the hepatic asialoglycoprotein receptor (ASGPR) for protein clearance (Stockert, Physiol Rev, 1995). These residues also serve as the essential binding motifs for galectins, a conserved family of lectins that modulate immune cell checkpoints, apoptosis, and cellular trafficking (Varki et al., Essentials of Glycobiology, 2017). In the tumor microenvironment, aberrant glycosylation often leads to an abundance of exposed terminal galactose, which facilitates Galectin-3-mediated immunosuppression and metastasis (Liu et al., Nat Rev Cancer, 2005). Consequently, these residues and their associated binding proteins are significant targets for therapeutic intervention, particularly in the development of galectin inhibitors and glyco-engineered biologics designed to optimize protein half-life and effector functions (Traber et al., Expert Opin Investig Drugs, 2013).

Other names

Terminal β-galactosyl residuesAsialo-N-glycansExposed galactoseβ-D-galactosyl groupsDesialylated N-glycansExposed β-galactosyl residues

These residues serve as the primary ligands for galectins and the asialoglycoprotein receptor (ASGPR). Therapeutic agents such as galectin inhibitors bind to the carbohydrate-recognition domain (CRD) of galectins to competitively inhibit their binding to terminal β-galactose residues, thereby disrupting pro-tumorigenic and immunosuppressive signaling pathways (Liu et al., Nat Rev Cancer, 2005; Traber et al., Expert Opin Investig Drugs, 2013).